Mutations in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) in human GH-secreting pituitary adenomas. Biochemical, clinical, and morphological aspects

A. Spada, M. Arosio, M. Bassetti, L. Vallar, E. Clementi, N. Bazzoni

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Very recently a subset of human GH-secreting pituitary adenomas carrying a somatic mutation in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) was identified. In all these tumors (Group 2; about 30% of all the GH secreting tumors studied) the alpha s cDNAs contained mutations; in 8 tumors mutations replaced arginine 201 with either cysteine or histidine while in the remaining tumors glutamine 227 was replaced by either arginine or leucine. No mutations were observed in the remaining adenomas (Group 1). The two mutations caused a constitutive activation of adenylyl cyclase and a turn on of cAMP synthesis by inhibiting GTPase activity. The transformed phenotype was reflected in adenomatous cells with high rate of cAMP production and in vitro GH secretion. No differences in age, sex, clinical features, duration of the disease and cure rate were observed between the patients without (Group 1) or with alpha s mutation (Group 2), while higher serum GH levels and smaller tumor size were present in Group 2 patients. Moreover, hypersecretory activity in Group 2 tumors was also apparent at electron microscopy: cells of Group 2 tumors were densely granulated and showed prominent rough endoplasmic reticulum and Golgi complex. With respect to Group 1, Group 2 patients were less responsive to GH-releasing hormone (GHRH), while they were more sensitive to somatostatin. The former finding is in agreement with the hypothesis that the oncogenic proteins mimic the effects of extracellular growth factors, so removing the requirement for GHRH; the latter might explain the low rate of tumor growth as due to the counteracting role of endogenous inhibitory factors.

Original languageEnglish
Pages (from-to)567-570
Number of pages4
JournalPathology Research and Practice
Volume187
Issue number5
Publication statusPublished - 1991

Fingerprint

Growth Hormone-Secreting Pituitary Adenoma
Adenylyl Cyclases
Mutation
Neoplasms
Proteins
Arginine
Hormones
Rough Endoplasmic Reticulum
GTP Phosphohydrolases
Golgi Apparatus
Somatostatin
Glutamine
Histidine
Leucine
Adenoma
Cysteine
Intercellular Signaling Peptides and Proteins
Electron Microscopy
Complementary DNA
Phenotype

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Mutations in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) in human GH-secreting pituitary adenomas. Biochemical, clinical, and morphological aspects. / Spada, A.; Arosio, M.; Bassetti, M.; Vallar, L.; Clementi, E.; Bazzoni, N.

In: Pathology Research and Practice, Vol. 187, No. 5, 1991, p. 567-570.

Research output: Contribution to journalArticle

@article{bd6760ebe0d941cd86ae75b344c9c75b,
title = "Mutations in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) in human GH-secreting pituitary adenomas. Biochemical, clinical, and morphological aspects",
abstract = "Very recently a subset of human GH-secreting pituitary adenomas carrying a somatic mutation in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) was identified. In all these tumors (Group 2; about 30{\%} of all the GH secreting tumors studied) the alpha s cDNAs contained mutations; in 8 tumors mutations replaced arginine 201 with either cysteine or histidine while in the remaining tumors glutamine 227 was replaced by either arginine or leucine. No mutations were observed in the remaining adenomas (Group 1). The two mutations caused a constitutive activation of adenylyl cyclase and a turn on of cAMP synthesis by inhibiting GTPase activity. The transformed phenotype was reflected in adenomatous cells with high rate of cAMP production and in vitro GH secretion. No differences in age, sex, clinical features, duration of the disease and cure rate were observed between the patients without (Group 1) or with alpha s mutation (Group 2), while higher serum GH levels and smaller tumor size were present in Group 2 patients. Moreover, hypersecretory activity in Group 2 tumors was also apparent at electron microscopy: cells of Group 2 tumors were densely granulated and showed prominent rough endoplasmic reticulum and Golgi complex. With respect to Group 1, Group 2 patients were less responsive to GH-releasing hormone (GHRH), while they were more sensitive to somatostatin. The former finding is in agreement with the hypothesis that the oncogenic proteins mimic the effects of extracellular growth factors, so removing the requirement for GHRH; the latter might explain the low rate of tumor growth as due to the counteracting role of endogenous inhibitory factors.",
author = "A. Spada and M. Arosio and M. Bassetti and L. Vallar and E. Clementi and N. Bazzoni",
year = "1991",
language = "English",
volume = "187",
pages = "567--570",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Elsevier GmbH",
number = "5",

}

TY - JOUR

T1 - Mutations in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) in human GH-secreting pituitary adenomas. Biochemical, clinical, and morphological aspects

AU - Spada, A.

AU - Arosio, M.

AU - Bassetti, M.

AU - Vallar, L.

AU - Clementi, E.

AU - Bazzoni, N.

PY - 1991

Y1 - 1991

N2 - Very recently a subset of human GH-secreting pituitary adenomas carrying a somatic mutation in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) was identified. In all these tumors (Group 2; about 30% of all the GH secreting tumors studied) the alpha s cDNAs contained mutations; in 8 tumors mutations replaced arginine 201 with either cysteine or histidine while in the remaining tumors glutamine 227 was replaced by either arginine or leucine. No mutations were observed in the remaining adenomas (Group 1). The two mutations caused a constitutive activation of adenylyl cyclase and a turn on of cAMP synthesis by inhibiting GTPase activity. The transformed phenotype was reflected in adenomatous cells with high rate of cAMP production and in vitro GH secretion. No differences in age, sex, clinical features, duration of the disease and cure rate were observed between the patients without (Group 1) or with alpha s mutation (Group 2), while higher serum GH levels and smaller tumor size were present in Group 2 patients. Moreover, hypersecretory activity in Group 2 tumors was also apparent at electron microscopy: cells of Group 2 tumors were densely granulated and showed prominent rough endoplasmic reticulum and Golgi complex. With respect to Group 1, Group 2 patients were less responsive to GH-releasing hormone (GHRH), while they were more sensitive to somatostatin. The former finding is in agreement with the hypothesis that the oncogenic proteins mimic the effects of extracellular growth factors, so removing the requirement for GHRH; the latter might explain the low rate of tumor growth as due to the counteracting role of endogenous inhibitory factors.

AB - Very recently a subset of human GH-secreting pituitary adenomas carrying a somatic mutation in the alpha subunit of the stimulatory regulatory protein of adenylyl cyclase (Gs) was identified. In all these tumors (Group 2; about 30% of all the GH secreting tumors studied) the alpha s cDNAs contained mutations; in 8 tumors mutations replaced arginine 201 with either cysteine or histidine while in the remaining tumors glutamine 227 was replaced by either arginine or leucine. No mutations were observed in the remaining adenomas (Group 1). The two mutations caused a constitutive activation of adenylyl cyclase and a turn on of cAMP synthesis by inhibiting GTPase activity. The transformed phenotype was reflected in adenomatous cells with high rate of cAMP production and in vitro GH secretion. No differences in age, sex, clinical features, duration of the disease and cure rate were observed between the patients without (Group 1) or with alpha s mutation (Group 2), while higher serum GH levels and smaller tumor size were present in Group 2 patients. Moreover, hypersecretory activity in Group 2 tumors was also apparent at electron microscopy: cells of Group 2 tumors were densely granulated and showed prominent rough endoplasmic reticulum and Golgi complex. With respect to Group 1, Group 2 patients were less responsive to GH-releasing hormone (GHRH), while they were more sensitive to somatostatin. The former finding is in agreement with the hypothesis that the oncogenic proteins mimic the effects of extracellular growth factors, so removing the requirement for GHRH; the latter might explain the low rate of tumor growth as due to the counteracting role of endogenous inhibitory factors.

UR - http://www.scopus.com/inward/record.url?scp=0025850364&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025850364&partnerID=8YFLogxK

M3 - Article

C2 - 1923949

AN - SCOPUS:0025850364

VL - 187

SP - 567

EP - 570

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 5

ER -